RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.200
0.00 (0.00%)
Dec 5, 2025, 4:00 PM EST - Market closed
RedHill Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 9.55 | 8.04 | 6.53 | 61.8 | 85.76 | 64.36 | Upgrade
|
| Revenue | 9.55 | 8.04 | 6.53 | 61.8 | 85.76 | 64.36 | Upgrade
|
| Revenue Growth (YoY) | 157.62% | 23.17% | -89.43% | -27.94% | 33.25% | 923.03% | Upgrade
|
| Cost of Revenue | 3.4 | 3.19 | 3.46 | 33.34 | 49.41 | 36.89 | Upgrade
|
| Gross Profit | 6.16 | 4.85 | 3.07 | 28.46 | 36.35 | 27.47 | Upgrade
|
| Selling, General & Admin | 12.45 | 15.52 | 30.98 | 64.03 | 87.99 | 74.66 | Upgrade
|
| Research & Development | 1.89 | 1.59 | 3.53 | 7.28 | 29.5 | 16.49 | Upgrade
|
| Other Operating Expenses | - | - | -8.56 | - | - | - | Upgrade
|
| Operating Expenses | 14.34 | 17.11 | 25.94 | 71.31 | 117.49 | 91.15 | Upgrade
|
| Operating Income | -8.18 | -12.25 | -22.87 | -42.84 | -81.14 | -63.68 | Upgrade
|
| Interest Expense | - | -0.06 | -0.37 | -41.33 | -16.57 | -12.45 | Upgrade
|
| Interest & Investment Income | 0.8 | 0.13 | 0.09 | 0.14 | 0.05 | 0.18 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.03 | -0.03 | -0.12 | -0.04 | -0.03 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.46 | 6.3 | -7.45 | 12.41 | -0.07 | -0.3 | Upgrade
|
| EBT Excluding Unusual Items | -6.95 | -5.91 | -30.71 | -71.67 | -97.74 | -76.27 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 35.5 | - | - | - | Upgrade
|
| Other Unusual Items | -2.36 | -2.36 | 19.13 | - | - | - | Upgrade
|
| Pretax Income | -9.31 | -8.27 | 23.92 | -71.67 | -97.74 | -76.17 | Upgrade
|
| Net Income | -9.31 | -8.27 | 23.92 | -71.67 | -97.74 | -76.17 | Upgrade
|
| Net Income to Common | -9.31 | -8.27 | 23.92 | -71.67 | -97.74 | -76.17 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 97.35% | 375.56% | 320.45% | 32.46% | 27.72% | 22.69% | Upgrade
|
| EPS (Basic) | -6.02 | -6.71 | 92.30 | -1162.89 | -2100.80 | -2091.06 | Upgrade
|
| EPS (Diluted) | -6.02 | -6.71 | 92.30 | -1162.89 | -2100.80 | -2091.06 | Upgrade
|
| Free Cash Flow | -8.21 | -9.38 | -35.83 | -29.38 | -65.16 | -48.99 | Upgrade
|
| Free Cash Flow Per Share | -5.31 | -7.61 | -138.28 | -476.76 | -1400.52 | -1344.71 | Upgrade
|
| Gross Margin | 64.45% | 60.31% | 47.03% | 46.06% | 42.39% | 42.68% | Upgrade
|
| Operating Margin | -85.70% | -152.36% | -350.20% | -69.33% | -94.61% | -98.95% | Upgrade
|
| Profit Margin | -97.52% | -102.80% | 366.25% | -115.97% | -113.98% | -118.36% | Upgrade
|
| Free Cash Flow Margin | -85.98% | -116.60% | -548.71% | -47.55% | -75.98% | -76.11% | Upgrade
|
| EBITDA | -8.34 | -12.16 | -22.15 | -34.69 | -62.99 | -54.94 | Upgrade
|
| EBITDA Margin | -87.29% | -151.14% | - | -56.13% | -73.45% | -85.36% | Upgrade
|
| D&A For EBITDA | -0.15 | 0.1 | 0.71 | 8.15 | 18.15 | 8.75 | Upgrade
|
| EBIT | -8.18 | -12.25 | -22.87 | -42.84 | -81.14 | -63.68 | Upgrade
|
| EBIT Margin | -85.70% | -152.36% | - | -69.33% | -94.61% | -98.95% | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.